An increasing number of studies suggest that compromising the G2–M checkpoint may allow enhanced genotoxic drug therapy [48–50, 64], prompting us to explore the synergistic tumour-killing effects of targeting SHCBP1 combined with low-dose DNA-damaging agents in vitro and in vivo. This evidence concerns the gene SHCBP1 and neoplasm.